Cleo Diagnostics (ASX:COV) Total Equity : A$10.54 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Total Equity?

Cleo Diagnostics's total equity for the quarter that ended in Dec. 2023 was A$10.54 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Cleo Diagnostics Total Equity Historical Data

The historical data trend for Cleo Diagnostics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Total Equity Chart

Cleo Diagnostics Annual Data

Trend

Jun23

Total Equity

-0.94

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
Total Equity	-0.33	-0.94	10.54

Cleo Diagnostics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Cleo Diagnostics's Total Equity for the fiscal year that ended in Jun. 2023 is calculated as

Total Equity	=	Total Assets(Q: Jun. 2023 )	-	Total Liabilities(Q: Jun. 2023 )
	=	1.077	-	2.02
	=	-0.94

Cleo Diagnostics's Total Equity for the quarter that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	10.739	-	0.199
	=	10.54

Cleo Diagnostics Total Equity Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines